LUX INFUSION
LIVE

Serial Number

99451691

Owner

BioMatrix Specialty Pharmacy, LLC

Attorney

Gina L. Durham

Filing Date

Oct 20, 2025

Add to watchlist:

No watchlists yet
View on USPTO

LUX INFUSION Trademark

Serial Number: 99451691

LUX INFUSION is a trademark filed by BioMatrix Specialty Pharmacy, LLC on October 20, 2025. The trademark is classified under Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

BioMatrix Specialty Pharmacy, LLC (7 trademarks)

855 SW 78th Ave., #C200
Plantation, FL 33324

Entity Type: 16

Trademark Details

Filing Date

October 20, 2025

Registration Date

Not Registered

Goods & Services

Retail pharmacy services; Specialized retail pharmacy services for patients with particular medical conditions; Pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies; Health care utilization and review services; Pharmaceutical cost management services and drug utilization review services; Business administration of pharmacy reimbursement programs and services

Intravenous (IV) hydration therapy services; Medical services, namely, providing and administering infusion biologics therapies for transplant, immunology, neurology and hematology patients; Home health care services, namely, dispensing and administering of infusion pharmaceuticals and nutritional therapy; Home-visit nursing care; Skilled nursing care services; Providing medical information to patients and medical professionals in the form of reports in the field of prescription drugs, drug therapies and infusion biologics therapies for transplant, immunology, neurology and hematology; Consulting services in the field of health; Medical consultations; Consulting in the field of health for persons with chronic health issues; Medical services, namely, immunization services; Medical evaluation services, namely, functional assessment of disease management programs for patients receiving medical services for purposes of guiding treatment and assessing program effectiveness; Health assessment services; Conducting medical physical evaluations; Medical evaluation of patients with transplants, and immunological, neurological, and hematological diseases and disorders; Medical evaluation of patients with chronic diseases, particularly, transplant diseases, and immunological, neurological, rheumatological, gastrointestinal, dermatological, hematological, and rare neurological, immunological, gastrointestinal, dermatological, rheumatological, hematological diseases and disorders; Providing medical advice in the field of transplant, immunology, neurology and hematology; Health care services, namely, disease management programs; Consulting services in the field of nursing; Medical assistance consultancy provided by doctors and other specialized medical personnel; Medical consultations provided via phone, online chat or videoconferencing; Intravenous (IV) vitamin therapy services; Health consulting relating to dispensing of pharmaceuticals and pharmaceutical advice

Filing History

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 13, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
May 13, 2026 GNSL
SUSPENSION LETTER WRITTEN
May 13, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 12, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 12, 2026 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 12, 2026 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 19, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 19, 2026 GNSL
SUSPENSION LETTER WRITTEN
Apr 19, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 17, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 17, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 17, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 6, 2026 GNRN
NON-FINAL ACTION E-MAILED
Mar 6, 2026 GNRT
NON-FINAL ACTION WRITTEN
Mar 6, 2026 CNRT
ASSIGNED TO EXAMINER
Mar 6, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 20, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 20, 2025 NWOS
NEW APPLICATION ENTERED
Oct 20, 2025 NWAP